Adentri Will Earn Decision Resources' Clinical Gold Standard Status for Acute Heart Failure in 2012, According to a New Report from Decision Resources
WALTHAM, Mass., March 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists indicate that a therapy's effect on the rate of mortality is the attribute that most influences their prescribing decisions in acute heart failure. Clinical data and the opinions of interviewed thought leaders indicate that Biogen Idec's Adentri has advantages in this attribute over nitroglycerin, the benchmark therapy in the market.
The new report entitled Acute Heart Failure: Finding Positive Outcomes in an Evidence Poor Indication finds that an agent with superior reduction in the rate of mortality compared with nitroglycerin would earn a 50 percent patient share in the United States and a 55 percent patient share in Europe, according to our survey of U.S. and European cardiologists.
In 2008, Decision Resources' proprietary clinical gold standard for acute heart failure was Scios/Johnson & Johnson's Natrecor. Interviewed experts generally regard Natrecor as being similarly efficacious as the benchmark therapy, nitroglycerin, but with a slightly better safety profile (e.g. fewer associated headaches). Based on available data and expert opinion, Adentri will earn gold-standard status for acute heart failure in 2012, following its approval for the indication. Adentri has competitive advantages because it will be one of the first adenosine A1 receptor antagonists for use in acute heart failure.
"Interviewed physicians believe that this class of drugs and, particularly, Adentri can provide a feasible and safe therapy when used in combination with loop diuretics," said Decision Resources Analyst Amir Mobasheri. "Interviewed physicians indicated that they prefer this oral agent and believe it will have the advantage of enhancing diuresis while preserving renal function."
About the Report
Acute Heart Failure: Finding Positive Outcomes in an Evidence Poor Indication is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 email@example.com firstname.lastname@example.org
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved